NO20022711L - Fremgangsmåte for testing av et terapeutisk eller profylaktisk middel for hyperlipidemi - Google Patents
Fremgangsmåte for testing av et terapeutisk eller profylaktisk middel for hyperlipidemiInfo
- Publication number
- NO20022711L NO20022711L NO20022711A NO20022711A NO20022711L NO 20022711 L NO20022711 L NO 20022711L NO 20022711 A NO20022711 A NO 20022711A NO 20022711 A NO20022711 A NO 20022711A NO 20022711 L NO20022711 L NO 20022711L
- Authority
- NO
- Norway
- Prior art keywords
- hyperlipidemia
- testing
- therapeutic
- prophylactic agent
- prophylactic
- Prior art date
Links
- 208000031226 Hyperlipidaemia Diseases 0.000 title abstract 4
- 230000000069 prophylactic effect Effects 0.000 title abstract 4
- 238000010998 test method Methods 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000002853 nucleic acid probe Substances 0.000 abstract 2
- 238000012360 testing method Methods 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5067—Liver cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Ny fremgangsmåte for testing av et terapeutisk middel eller et profylaktisk middel for hyperlipidemi, og nukleinsyreprobe, primer og antistoff som anvendes ved fremgangsmåten. Nærmere bestemt fremgangsmåte for testing av virkningen av et prøvestoff som terapeutisk middel eller profylaktisk middel for hyperlipidemi, ved å anvende ekspresjonen av et gen representert ved SEQ ID No. 1 eller 2 i sekvenslisten, som deltar i kontrollen av nøytralfettnivået i blodet hos pattedyr, som en indikasjon, og nukleinsyreprobe, primer og antistoff som anvendes ved denne fremgangsmåten. Ved å anvende denne fremgangsmåten kan det letes etter kandi-dater til profylaktiske eller terapeut-iske midler for hyperlipidemi.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP34997699 | 1999-12-09 | ||
PCT/JP2000/008722 WO2001042499A1 (fr) | 1999-12-09 | 2000-12-08 | Procede d'essai d'agent curatif ou preventif de l'hyperlipemie |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20022711D0 NO20022711D0 (no) | 2002-06-07 |
NO20022711L true NO20022711L (no) | 2002-08-08 |
Family
ID=18407394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20022711A NO20022711L (no) | 1999-12-09 | 2002-06-07 | Fremgangsmåte for testing av et terapeutisk eller profylaktisk middel for hyperlipidemi |
Country Status (17)
Country | Link |
---|---|
US (3) | US20030017488A1 (no) |
EP (1) | EP1239050A4 (no) |
KR (1) | KR20020062652A (no) |
CN (1) | CN1433482A (no) |
AU (1) | AU768034B2 (no) |
BR (1) | BR0016257A (no) |
CA (1) | CA2390676A1 (no) |
CZ (1) | CZ20021853A3 (no) |
HK (1) | HK1045541A1 (no) |
HU (1) | HUP0203408A3 (no) |
IL (1) | IL149849A0 (no) |
MX (1) | MXPA02005758A (no) |
NO (1) | NO20022711L (no) |
PL (1) | PL355666A1 (no) |
RU (1) | RU2002115295A (no) |
WO (1) | WO2001042499A1 (no) |
ZA (1) | ZA200204432B (no) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030039986A1 (en) * | 2000-11-03 | 2003-02-27 | Yongming Sun | Compositions and methods relating to prostate specific genes and proteins |
IL159153A0 (en) * | 2001-06-08 | 2004-06-01 | Sankyo Co | Methods for testing drugs for treating or preventing diseases such as hyperlipidemia |
WO2003028445A1 (fr) * | 2001-08-31 | 2003-04-10 | Otsuka Pharmaceutical Co., Ltd. | Animal rendu inconscient tsa2306 |
WO2008073300A2 (en) | 2006-12-08 | 2008-06-19 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angptl3 |
US8143600B2 (en) * | 2008-02-18 | 2012-03-27 | Visiongate, Inc. | 3D imaging of live cells with ultraviolet radiation |
US8653047B2 (en) | 2010-01-08 | 2014-02-18 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
RU2650510C2 (ru) | 2013-05-01 | 2018-04-16 | Ионис Фармасьютикалз, Инк. | Композиции и способы модулирования экспрессии аполипопротеина c-iii |
PL3087183T3 (pl) | 2013-12-24 | 2021-01-11 | Ionis Pharmaceuticals, Inc. | Modulacja ekspresji białka angiopoetynopodobnego 3 |
BR112016024850B1 (pt) | 2014-05-01 | 2021-07-06 | Ionis Pharmaceuticals, Inc | compostos e composições para modulação da expressão de angptl3 e seus usos |
CN108348478A (zh) | 2015-11-06 | 2018-07-31 | Ionis 制药公司 | 调节载脂蛋白(a)表达 |
PE20201287A1 (es) | 2017-09-14 | 2020-11-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso |
CN109806632A (zh) * | 2019-03-01 | 2019-05-28 | 中国科学院武汉物理与数学研究所 | 一种全血过滤装置 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6030831A (en) * | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
AU3661199A (en) * | 1998-04-27 | 1999-11-16 | Zymogenetics Inc. | Novel polypeptide growth factors and materials and methods for making them |
JP2002533058A (ja) * | 1998-05-12 | 2002-10-08 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 97個のヒト分泌タンパク質 |
SV1999000069A (es) * | 1998-06-02 | 2000-04-11 | Lilly Co Eli | Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261 |
WO1999067382A2 (en) * | 1998-06-24 | 1999-12-29 | Compugen Ltd. | Angiopoietin-like growth factor sequences |
WO2000029448A2 (en) * | 1998-11-17 | 2000-05-25 | Sagami Chemical Research Center | Human proteins having hydrophobic domains and dnas encoding these proteins |
MXPA01005169A (es) * | 1998-12-01 | 2002-07-02 | Genentech Inc | Promocion o inhibicion deangiogenesis y cardiovascularizacion. |
DK1484338T3 (da) * | 1998-12-22 | 2007-06-11 | Genentech Inc | Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst |
US20020015950A1 (en) * | 1999-07-07 | 2002-02-07 | Karen Anne Jones | Atherosclerosis-associated genes |
US20020054871A1 (en) * | 1999-04-12 | 2002-05-09 | Yadong Huang | Methods and compositions for use in the treatment of hyperlipidemia |
JP2000325087A (ja) * | 1999-05-21 | 2000-11-28 | Otsuka Pharmaceut Co Ltd | Tsa2306遺伝子 |
AU6605900A (en) * | 1999-07-16 | 2001-02-05 | Hyseq, Inc. | Novel angiopoietin materials and methods |
ATE368110T1 (de) * | 1999-07-20 | 2007-08-15 | Genentech Inc | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten |
-
2000
- 2000-12-08 IL IL14984900A patent/IL149849A0/xx unknown
- 2000-12-08 HU HU0203408A patent/HUP0203408A3/hu unknown
- 2000-12-08 WO PCT/JP2000/008722 patent/WO2001042499A1/ja not_active Application Discontinuation
- 2000-12-08 CN CN00818875A patent/CN1433482A/zh active Pending
- 2000-12-08 KR KR1020027007206A patent/KR20020062652A/ko not_active Application Discontinuation
- 2000-12-08 AU AU18870/01A patent/AU768034B2/en not_active Ceased
- 2000-12-08 EP EP00981649A patent/EP1239050A4/en not_active Withdrawn
- 2000-12-08 BR BR0016257-4A patent/BR0016257A/pt not_active IP Right Cessation
- 2000-12-08 PL PL00355666A patent/PL355666A1/xx not_active Application Discontinuation
- 2000-12-08 CA CA002390676A patent/CA2390676A1/en not_active Abandoned
- 2000-12-08 MX MXPA02005758A patent/MXPA02005758A/es unknown
- 2000-12-08 CZ CZ20021853A patent/CZ20021853A3/cs unknown
- 2000-12-08 RU RU2002115295/15A patent/RU2002115295A/ru not_active Application Discontinuation
-
2002
- 2002-06-06 US US10/164,030 patent/US20030017488A1/en not_active Abandoned
- 2002-06-07 NO NO20022711A patent/NO20022711L/no not_active Application Discontinuation
- 2002-09-25 HK HK02106979.0A patent/HK1045541A1/zh unknown
-
2003
- 2003-06-03 ZA ZA200204432A patent/ZA200204432B/en unknown
- 2003-06-11 US US10/460,124 patent/US20030211533A1/en not_active Abandoned
- 2003-06-11 US US10/460,125 patent/US20030207251A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2002115295A (ru) | 2004-01-10 |
NO20022711D0 (no) | 2002-06-07 |
HUP0203408A2 (hu) | 2003-01-28 |
CN1433482A (zh) | 2003-07-30 |
KR20020062652A (ko) | 2002-07-26 |
EP1239050A1 (en) | 2002-09-11 |
CZ20021853A3 (cs) | 2002-11-13 |
CA2390676A1 (en) | 2001-06-14 |
WO2001042499A1 (fr) | 2001-06-14 |
MXPA02005758A (es) | 2002-09-18 |
US20030211533A1 (en) | 2003-11-13 |
US20030207251A1 (en) | 2003-11-06 |
AU768034B2 (en) | 2003-11-27 |
EP1239050A4 (en) | 2004-07-21 |
IL149849A0 (en) | 2002-11-10 |
PL355666A1 (en) | 2004-05-04 |
AU1887001A (en) | 2001-06-18 |
ZA200204432B (en) | 2003-09-29 |
BR0016257A (pt) | 2002-08-20 |
US20030017488A1 (en) | 2003-01-23 |
HK1045541A1 (zh) | 2002-11-29 |
HUP0203408A3 (en) | 2005-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lam et al. | Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome | |
Stadtman | Protein modification in aging | |
NO20022711L (no) | Fremgangsmåte for testing av et terapeutisk eller profylaktisk middel for hyperlipidemi | |
EP0621284A4 (en) | PEPTIDES CONTAINING SELECTED RESPECTIVE AMINO ACID SELECTED FROM LIPOPROTEIN (a) AND APOLIPOPROTEIN (a), ANTIBODIES RECOGNIZING THESE AMINO ACID SEQUENCES AND ANALYSIS METHOD USING THE SAME. | |
DK1187591T3 (da) | IBD-associerede mikrobielle antigener og fremgangsmåder til at anvende samme | |
WO2001012662A3 (en) | Membrane associated proteins | |
DK104093D0 (da) | Fremgangsmaade til bestemmelse af collagen-fragmenter i legemsvaesker, test-kit og midler til udoevelse af fremgangsmaaden og anvendelse af fremgangsmaaden til diagnosticering af lidelser associeret til collagen-metabolismen | |
NO881670L (no) | Diagnostisk proeve paa inhibitor for plasminogenaktivatorerav vev- og urokinasetype, samt gen som koder for inhibitoren. | |
MX9606463A (es) | Secuencias de nucleotido de las cepas pestivirus, polipeptidos codificados por estas secuencias y usos de los mismos para la diagnosis y prevencion de infecciones con pestivirus. | |
Burgos et al. | Analysis of the activation process of porcine procarboxypeptidase B and determination of the sequence of its activation segment | |
Britto‐Júnior et al. | Endothelium‐derived dopamine modulates EFS‐induced contractions of human umbilical vessels | |
EE200100040A (et) | Meetod raku fenotüüpi muutva modulaatori identifitseerimiseks ja valmistamiseks, sihtmärkbiomolekulide eraldamiseks ja/või samastamiseks ning meditsiinitoote arendamiseks ja valmistamiseks | |
SE8802944L (sv) | Material foer lapptestning | |
DK328584D0 (da) | Immunobestemmelsesmetode for en iodthyronin i en biologisk vaeske samt reagenssystem, testsaet og testmateriale til anvendelse ved metoden | |
AU2126400A (en) | Detection of small molecules by use of a piezoelectric sensor | |
NO970518L (no) | Probe-system som tillater HLA-DR-typing samt fremgangsmåte ved anvendelse av slike prober | |
NO20006153L (no) | Poly(ADP-ribose)polymerase gen | |
ATE255595T1 (de) | Nephrin gen und protein | |
DE69840268D1 (de) | Biologisches testverfahren für thyroid stimulierende antikörper | |
WO2001044448A3 (en) | Human oxidoreductase proteins | |
Kivlen et al. | Asymmetric distribution of pause transfer sequences in apolipoprotein B-100 | |
KR960703434A (ko) | D4 도파민 수용체의 합성 유전자(a synthetic gene for d4 dopamine receptors) | |
AU2002257284A1 (en) | Pna probes, probe sets, methods and kits pertaining to the detection of candida | |
Bonnet et al. | Differential phosphorylation of Cdc25C phosphatase in mitosis | |
Morollo et al. | Isolation and structure determination of 2-amino-2-deoxyisochorismate: an intermediate in the biosynthesis of anthranilate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |